FORM 8-KA


                       SECURITIES AND EXCHANGE COMMISSION
                               WASHINGTON DC 20549


                                 CURRENT REPORT



     Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934






                       MEDISCIENCE TECHNOLOGY CORPORATION
               (EXACT NAME OF REGISTRANT AS SPECIFIED ON CHARTER)



  NEW JERSEY                     0-7405                       22-1937826
________________________________________________________________________________
(State of Incorporation) (Commission File No.) (IRS Employer Identification No.)




         1235 Folkstone Way, P.O. Box 598, Cherry Hill, New Jersey 08003
________________________________________________________________________________




        Registrant's telephone number. Including area code (856) 428 7952
________________________________________________________________________________





________________________________________________________________________________
                 (Former Address, if changed, since last report)






Item 5. Other Materially Important Events:

                      Amendment of 8-K filed JUNE 12, 2002

The new  contract  with the  Research  Foundation  City  University  of New York
(RFCUNY) was effective upon acceptance by Registrant on June 10th, 2002.

Registrant  executed a new contract with the Research Foundation City University
of New York (RFCUNY), that supercedes all prior agreements with (RFCUNY), erases
all MTC debt to RFCUNY and reduces  MTC royalty  rate from 5% to 3.25% as to all
patent/patent  applications  of a Medical  nature in exchange for the  following
consideration  to  (RFCUNY):  1.  Registrant's  cash payment of  $85,045.00,  2.
Registrant's  issuance  to RFCUNY of  283,228  SEC144  shares.  3.  Registrant's
issuing a five (5) year.  Warrant to (RFCUNY)  providing  (RFCUNY)  the right to
purchase six hundred thousand  (600,000) SEC144 shares at one dollar ($1.00) per
share. The agreement  protects  Registrant by affirming  Registrant's  ownership
and/or  exclusive  license of all MEDICAL  APPLICATIONS  embodied in Registrants
patent list  attached to the contract as exhibit A. RFCUN has a prior warrant to
purchase five hundred thousand  (500,000) shares of Mediscience  common Rule 144
shares at one  dollar  ($1.00)  per share  expiring  December  31,  2003.  Total
warrants  presently  in RFCUNY  for  Mediscience  common  SEC 144  shares is One
Million one hundred thousand (1,100,000).



B Effective June 10th, 2002 and  unanimously  approved by the Board of Directors
May 30, 2002  Registrant  executed  and fully funded a new  agreement  with "The
Institute for Ultra fast Spectroscopy and Lasers Center for Ultrafast  Photonics
and Mediphotonics Laboratory of City University of New York". Term: July 1, 2002
to June 30,  2003.  The  agreement  provides  continual  technical  and research
assistance to Registrant in support of existing and anticipated  clinical trials
in the United States and India.



The cash  payment of $120,045 for the two above  transactions  was financed by a
promissory  note dated  June 20,  2002  between  the  company  and the Olive Cox
Sleeper  Trust ("the  Trust").  Terms of the note was interest at 12% per annum.
The principle  amount  outstanding on the note plus all accrued  interest is due
and payable on February 20,2003.

The note has a  conversion  feature  that  allows the  "Trust"  to  convert  the
principle and accrued  interest on the note on February 20, 2003 to Common Stock
of the Company at the rate of one share for each $0.12 of principle  and accrued
interest at date of conversion.





                                   SIGNATURES



Pursuant to the  requirements  of the  Securities  and Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized



                                      MEDISCIENCE TECHNOLOGY CORPORATION




                                      /s/ Peter Katevatis
                                      ------------------------------------------
                                      Peter Katevatis, Chairman


Dated July 30, 2002